

A photograph of an elderly patient lying in a hospital bed, wearing a patterned hospital gown. They are using the Aerogen COVID-19 aerosol delivery system, which consists of a white nebulizer connected to a blue corrugated tube. The patient's eyes are closed, and the device is positioned near their mouth. The background is a blurred hospital room.

AEROGEN[®] COVID-19 AEROSOL GUIDANCE

Aerogen is THE ONLY closed circuit aerosol drug delivery system that mitigates the transmission of patient generated infectious aerosol^{1,2} and delivers effective aerosol treatment.^{2,3,4}

Aerogen[®]
Pioneering Aerosol Drug Delivery

MECHANICAL VENTILATION



SAFETY

Aerogen is designed for the safety of both the patient and the caregiver.

- Aerogen maintains a closed ventilation circuit^{1,2}
- Separate medication cup²
- Enables drug delivery without breaking the circuit^{1,2}

Unlike pMDI and jet nebulizers.




EFFICACY




Closed circuit with Aerogen

Figure 1. Demonstrates the closed circuit with Aerogen technology.



Broken circuit with pMDI/JN

Figure 2 Demonstrates the break in a circuit with pMDI/jet nebulizer.



- Can be used for continuous and intermittent treatments.¹

2x more drug dose to the patient compared to pMDI⁵

5x more medication delivered to the lungs³ compared to a jet nebulizer⁴

HIGH FLOW



SAFETY

Aerogen is the only device that can deliver aerosol therapy efficiently during HFNC.^{6, 7}

- No break in the therapy during delivery.^{6, 7}
- Reduced risk of de-recruitment of the lung.^{6, 7}
- Reduced dispersion of patient generated bioaerosols and medical aerosols with placement of a surgical mask on the face of patients.^{2, 8, 9}




EFFICACY

Aerogen delivers a **positive bronchodilator response** in COPD and asthma patients with HFNC.¹⁰


3.5-17%

3.5-17% medication delivery to the lungs, depending on flow rates, with Aerogen¹¹


Aerogen Aerosol delivery during HFNC¹¹



50L/MIN



30L/MIN



10L/MIN

Aerogen®

Pioneering Aerosol Drug Delivery

SPONTANEOUS BREATHING PATIENTS




SAFETY

- **No increase** in exhaled environmental emissions with Aerogen Ultra when used with a filter compared to baseline.¹²
- Can be used with a bacterial or viral filter.¹




EFFICACY




6x

more medication delivered to the lungs compared to a jet nebulizer¹³, resulting in improved patient response to treatment¹⁴




AEROGEN ULTRA¹³



85%

patients achieved symptom control with one 2.5mg albuterol dose.¹⁵
Reduction in number of treatments and bronchodilator use¹⁶



JET NEBULIZER¹³

Aerogen[®]

Pioneering Aerosol Drug Delivery

TRUST AEROGEN



Global

Aerogen technology is featured in guidelines and papers on the treatment of COVID-19 patients from across the globe.^{2, 17, 18}



1,500+

hospital systems in the US use Aerogen¹⁹



10m+

Patients treated worldwide¹⁹



6x

AARC Zenith award winner¹⁹




Vaccines

Partners of choice for multiple companies developing treatments and vaccines for COVID-19¹⁹



200+

Peer reviewed studies and reviews related to Aerogen technology¹⁹



Trusted

Trusted by the world's leading ventilator companies as the integrated aerosol drug delivery solution.¹⁹

CONTACT YOUR AEROGEN CCS

Name:

Phone:

Email:

REFERENCES

1. Aerogen Solo System Instruction Manual. Aerogen Ltd.
2. Ari, A. (2020). Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. In *Respiratory Medicine* (Vol. 167). W.B. Saunders Ltd. <https://doi.org/10.1016/j.rmed.2020.105987>
3. Dugernier J, Reyckler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T, et al. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. *Ann Intensive Care* [Internet]. 2016/07/23. 2016 Dec [cited 2018 Oct 5];6(1):73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27447788>
4. MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. *Crit Care Med* [Internet]. 1985/02/01. 1985 Feb [cited 2019 Apr 17];13(2):81–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/39675081>
5. Alhamad BR, Fink JB, Harwood RJ, Sheard MM, Ari A. Effect of Aerosol Devices and Administration Techniques on Drug Delivery in a Simulated Spontaneously Breathing Pediatric Tracheostomy Model. *Respir Care* 2015; 60: 1026–1032.
6. Dugernier J, Hesse M, Jumetz T, Bialais E, Roeseler J, Depoortere V, et al. Aerosol Delivery with Two Nebulizers Through High Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*. 2017; 30: 1-10 5
7. Reminiac F, Vecellio L, Loughlin R Mac, Le Pennec D, Cabrera M, Vourc'h NH, et al. Nasal high flow nebulization in infants and toddlers: An in vitro and in vivo scintigraphic study. *Pediatr Pulmonol*. 2016/07/09. 2017;52(3):337–44.
8. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bioaerosol dispersion. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.00892-2020>).
9. Leonard S, Atwood CW Jr, Walsh BK, DeBellis RJ, Dungan GC, Strasser W, Whittle JS. Preliminary findings of control of dispersion of aerosols and droplets during high velocity nasal insufflation therapy using a simple surgical mask Implications for high flow nasal cannula. *Chest*. 2020 Apr 2. pii: S0012-3692(20)30579-1. doi:10.1016/j.chest.2020.03.043. [Epub ahead of print]
10. Li J, Zhao M, Hadeer M, Luo J, Fink JB. Dose Response to Transnasal Pulmonary Administration of Bronchodilator Aerosols via Nasal High-Flow Therapy in Adults with Stable Chronic Obstructive Pulmonary Disease and Asthma. *Respiration* 2019; 98: 401–409.
11. Alcoforado L, Ari A, Barcelar J, Brandão S, Fink J, de Andrade A. Impact of Gas Flow and Humidity on Trans-Nasal Aerosol Deposition via Nasal Cannula in Adults: A Randomized Cross-Over Study. *Pharmaceutics* 2019; 11: 320.
12. McGrath JA, O'Sullivan A, Bennett G, O'Toole C, Joyce M, Byrne MA, et al. Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. *Pharmaceutics*. 2019 Feb 1;11(2).
13. Dugernier J et al. SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-Mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study. *Pharmaceutical Research*. 2017;34:290-300.
14. Chweich H et al. Effect on Airflow of Bronchodilator Therapy Delivered via Vibrating- Mesh versus Jet Nebulizers in Acute Asthmatics in an Emergency Department. Poster at ATS. 2019.
15. Dunne RB and Shortt S. Comparison of bronchodilator administration with vibrating mesh nebulizer and standard jet nebulizer in the emergency department. *The American Journal of Emergency Medicine*. 2018;36(4):641-646.
16. Moody GB, Luckett PM, Shockley CM, Huang R, Ari A. Clinical Efficacy of Vibrating Mesh and Jet Nebulizers With Different Interfaces in Pediatric Subjects With Asthma. *Respir Care* 2020; : respcare.07538.
17. American Association of Respiratory Care. AARC Guidance CoV-2. <https://www.aarc.org/wpcontent/uploads/2020/03/guidance-document-SARS-COVID19.pdf> (accessed 20May2020).
18. Respiratory Therapy Group, Respiratory Medicine Branch, Chinese Medical Association. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020. doi:10.3760/cma.j.issn.1001-0939.2020.0020.
19. Aerogen Internal data on file, Aug 2020.

For more information visit:
www.aerogen.com/covid-19

/ Discover Better

Aerogen®